Amphotericin B Treatment for Indian Visceral Leishmaniasis: Conventional versus Lipid Formulations

Clinical Infectious Diseases

Volumn 38, Issue 3, 2004, Pages 377-383

  Sundar, Shyam ^a,c   Mehta, Himanshu ^a   Suresh, A V ^a   Singh, Shri P ^a   Rai, Madhukar ^a   Murray, Henry W ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SCREENING; FEMALE; HUMAN; HYPOKALEMIA; INDIA; INFUSION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REDUCTION; RELAPSE; RIGOR; SIDE EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

ADOLESCENT; ADULT; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DEOXYCHOLIC ACID; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HOSPITAL COSTS; HUMANS; INDIA; INFANT; LEISHMANIASIS, VISCERAL; LIPOSOMES; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS; TREATMENT OUTCOME;

EID: 1042288575     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/380971     Document Type: Article

References (19)

1. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-6.
2. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.
3. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 6:849-54.
4. Murray HW. Treatment of visceral leishmaniasis (kala-azar): a decade of progress and future approaches. Int J Infect Dis 2000; 4:158-77.
5. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
6. Murray HW. Clinical and experimental advances in treatment in visceral leishmaniasis. Antimicrob Agents Chemother 2001; 45:2185-97.
7. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A. Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 1999; 93:319-23.
8. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis - a multicenter study. Am J Trop Med Hyg 2002; 66:143-6.
9. Sundar S, Agrawal NK, Sinha PR, Horwith GS, Murray HW. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997; 127: 133-7.
10. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. BMJ 2001; 323: 419-22.
11. Syriopoulou V, Daikos GL, Theodoridou M, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36:560-6.
12. Dietze R, Fagundes SMS, Brito EF, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B colloidal dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89:309-11.
13. Gaeta GB, Maisto A, Di Caprio D, et al. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients. Scand J Infect Dis 2000; 32:675-7.
14. Sundar S. Treatment of visceral leishmaniasis. Med Microbiol Immunol 2001; 190:89-92.
15. Thakur CP. Socio-economics of visceral leishmaniasis in Bihar (India). Trans R Soc Trop Med Hyg 2000; 94:156-7.
16. Bennett JE. Amphotericin B. In: Hardman JC, Limbird LE, eds. Goodman & Gilman's pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:1295-9.
17. Sundar S, Goyal AK, Mandal AK, Makharia MK, Singh VP, Murray HW. Amphotericin B lipid complex in the management of antimony-unresponsive Indian visceral leishmaniasis. J Assoc Physicians India 1999; 47:186-8.
18. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25-32.
19. Perez-Casas C, Herranz E, Ford N. Pricing of drugs and donations: options for sustainable equity pricing. Trop Med Int Health 2001; 6: 960-4.